Jim Cramer Shows Confidence in Amgen

Group 1 - Amgen Inc. is gaining attention for its potential in the healthcare sector, particularly with its cholesterol drug Repatha and weight loss treatments, which could lead to significant outcomes [1][2] - The stock has increased approximately 20% from its lows in late September, driven by strong quarterly results and promising clinical trial outcomes for heart attack prevention [2] - The healthcare sector, including Amgen, is considered undervalued, with analysts noting that it is an opportune time to invest in such stocks [2]